“Biostock Interview: Chordate CEO Anders Weilandt on Patent Approval in the US

Biostock interviews Chordate Medical’s CEO Anders Weilandt about the upcoming patent approval by the US Patent Office, how the American migraine market differs from the European one, and the company’s next step in obtaining FDA approval for Ozilia in the US.

“The project is currently awaiting the publication of the article from the migraine study PM007. We need to have it in place to take the next step in the FDA project.”

Read the full interview

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy